Clinical significance of Polycomb gene expression in brain tumors

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Crea, Francesco ^a,b   Hurt, Elaine M ^a   Farrar, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCOMB GROUP PROTEIN; PROTEIN SUZ12; RETINOBLASTOMA BINDING PROTEIN 7; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR YY1; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; ASTROCYTOMA; CELL CYCLE; CELL MOTION; GANGLIONEUROMA; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; MEDULLOBLASTOMA; OLIGODENDROGLIOMA; PROGNOSIS; RHABDOID TUMOR; ADULT; BRAIN TUMOR; CHILD; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY;

ADULT; BRAIN NEOPLASMS; CHILD; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; PROGNOSIS; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS;

EID: 77957193274     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-265     Document Type: Article

References (23)

1. Kaderali Z, Lamberti-Pasculli M, Rutka JT. The changing epidemiology of paediatric brain tumours: a review from the Hospital for Sick Children. Childs Nerv Syst 2009, 25:787-793. 10.1007/s00381-008-0771-9, 19082611.
2. MacDonald TJ, Rood BR, Santi MR, Vezina G, Bingaman K, Cogen PH, Packer RJ. Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors. Oncologist 2003, 8:174-186. 10.1634/theoncologist.8-2-174, 12697942.
3. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathologica 2005, 109:93-108. 10.1007/s00401-005-0991-y, 15685439.
4. Nagarajan RP, Costello JF. Epigenetic mechanisms in glioblastoma multiforme. Semin Cancer Biol 2009, 19:188-197. 10.1016/j.semcancer.2009.02.005, 19429483.
5. Mathews LA, Crea F, Farrar WL. Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation 2009, 78:1-17. 10.1016/j.diff.2009.04.002, 2706282, 19443100.
6. Vogel T, Stoykova A, Gruss P. Differential expression of polycomb repression complex 1 (PRC1) members in the developing mouse brain reveals multiple complexes. Dev Dyn 2006, 235:2574-2585. 10.1002/dvdy.20876, 16786585.
7. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401. 10.1038/nature03128, 15549107.
8. Salmaggi A, Boiardi A, Gelati M, Russo A, Calatozzolo C, Ciusani E, Sciacca FL, Ottolina A, Parati EA, La Porta C, et al. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 2006, 54:850-860. 10.1002/glia.20414, 16981197.
9. Fu J, Liu ZG, Liu XM, Chen FR, Shi HL, Pangjesse CS, Ng HK, Chen ZP. Glioblastoma stem cells resistant to temozolomide-induced autophagy. Chin Med J (Engl) 2009, 122:1255-1259.
10. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008, 14:123-129. 10.1158/1078-0432.CCR-07-0932, 18172261.
11. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009, 8:806-823. 10.1038/nrd2137, 19794444.
12. Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, et al. EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance. Cancer Res 2009,
13. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008, 40:499-507. 10.1038/ng.127, 2912221, 18443585.
14. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. Embo J 2003, 22:5323-5335. 10.1093/emboj/cdg542, 213796, 14532106.
15. Hayry V, Tanner M, Blom T, Tynninen O, Roselli A, Ollikainen M, Sariola H, Wartiovaara K, Nupponen NN. Copy number alterations of the polycomb gene BMI1 in gliomas. Acta Neuropathol 2008, 116:97-102. 10.1007/s00401-008-0376-0, 18427816.
16. Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 2009, 29:8884-8896. 10.1523/JNEUROSCI.0968-09.2009, 19605626.
17. Chang CJ, Hsu CC, Yung MC, Chen KY, Tzao C, Wu WF, Chou HY, Lee YY, Lu KH, Chiou SH, Ma HI. Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem Biophys Res Commun 2009, 380:236-242. 10.1016/j.bbrc.2009.01.040, 19166820.
18. Gieni RS, Hendzel MJ. Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer. Biochem Cell Biol 2009, 87:711-746. 10.1139/O09-057, 19898523.
19. Kohler C, Villar CB. Programming of gene expression by Polycomb group proteins. Trends Cell Biol 2008, 18:236-243. 10.1016/j.tcb.2008.02.005, 18375123.
20. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6. 1635162, 15068665.
21. Wang H, Ouyang Y, Somers WG, Chia W, Lu B. Polo inhibits progenitor self-renewal and regulates Numb asymmetry by phosphorylating Pon. Nature 2007, 449:96-100. 10.1038/nature06056, 17805297.
22. Dietzmann K, Kirches E, von B, Jachau K, Mawrin C. Increased human polo-like kinase-1 expression in gliomas. J Neurooncol 2001, 53:1-11. 10.1023/A:1011808200978, 11678424.
23. Degenhardt Y, Lampkin T. Targeting Polo-like kinase in cancer therapy. Clin Cancer Res 16:384-389. 10.1158/1078-0432.CCR-09-1380, 20068088.